Clinical Scorecard: Morphological Changes in the Cortex Associated with Psychosis Induced by Methamphetamine: Insights from a Surface-Based Morphometry Analysis
At a Glance
Category
Detail
Condition
Methamphetamine-induced psychosis (MAP) and methamphetamine use disorder (MUD)
Key Mechanisms
Neurostructural abnormalities in cortical and limbic brain regions including orbitofrontal cortex, striatum, amygdala, and hippocampus
Target Population
Male Han Chinese adults aged 18-55 with methamphetamine use disorder, with or without psychosis
Care Setting
Psychiatric and detoxification centers with neuroimaging and clinical assessment capabilities
Key Highlights
MAP affects approximately 43% of individuals with methamphetamine use disorder and is characterized by transient schizophreniform psychotic symptoms.
Neuroimaging reveals reduced cortical thickness and volumetric alterations in frontal, striatal, and limbic regions among METH users, particularly in those with psychosis.
Craving intensity, a core symptom of addiction and relapse trigger, is assessed using a visual analog scale and is linked to neurobiological substrates.
Guideline-Based Recommendations
Diagnosis
Use DSM-5 criteria for Substance/Medication-Induced Psychotic Disorder to diagnose MAP, requiring hallucinations and/or delusions temporally related to methamphetamine use.
Employ structured clinical interviews (e.g., SCID-5) conducted by qualified psychiatrists for accurate diagnosis.
Exclude other psychiatric disorders, delirium, or primary psychotic disorders to confirm MAP diagnosis.
Management
Provide care in specialized detoxification or psychiatric centers with multidisciplinary teams.
Monitor and address comorbid conditions such as nicotine dependence and other substance use.
Implement interventions targeting craving to reduce relapse risk.
Monitoring & Follow-up
Use neuroimaging (MRI) to assess structural brain changes associated with METH use and psychosis.
Evaluate craving intensity regularly using validated tools such as the visual analog scale (VAS).
Conduct ongoing clinical assessments to monitor psychotic symptoms and substance use patterns.
Risks
High risk of mortality, infectious diseases (HIV, hepatitis), cardiovascular complications, and deteriorated mental health including psychosis and suicidal tendencies.
MAP is associated with social consequences including risky behaviors, family breakdown, and legal challenges.
Potential for relapse driven by craving and neurobiological alterations.
Patient & Prescribing Data
Male Han Chinese adults aged 18-55 diagnosed with methamphetamine use disorder, subdivided into those with and without psychosis.
Diagnosis relies on clinical criteria and neuroimaging; craving assessment is essential for relapse prevention; management requires multidisciplinary approaches addressing both psychiatric symptoms and substance use.
Clinical Best Practices
Confirm MAP diagnosis through structured clinical interviews and consensus by experienced psychiatrists.
Exclude confounding psychiatric disorders and substance use to ensure diagnostic specificity.
Use validated scales such as FTND for nicotine dependence and VAS for craving to quantify clinical features.
Incorporate neuroimaging findings to understand and monitor brain structural changes related to METH use and psychosis.
Provide comprehensive care addressing psychiatric symptoms, substance use, and social consequences.
